The efficacy and safety of intravenous chlorpromazine treatment for delirium in incurable cancer patients with difficulty receiving oral administration.

The efficacy and safety of intravenous chlorpromazine treatment for delirium in incurable cancer patients with difficulty receiving oral administration. - The efficacy and safety of intravenous chlorpromazine treatment for delirium.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051317

Enrollment

Registered

2023-06-11

Start date

2018-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-reversible delirium

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The incurable cancer patients with difficulty receiving oral administration diagnosed with non-reversible delirium using the American Psychiatric Association's diagnostic criteria (DSM-V).

Exclusion criteria

Exclusion criteria: mental disorders such as dementia which would create difficulties communication before the onset of delirium

Design outcomes

Primary

Measure	Time frame
Nursing Delirium Screening Scale mean scores before and 3 days after intravenous chlorpromazine	—

Countries

Japan

Contacts

Public ContactRyohei Fujii

Kansai Medical University Hospital Department of Pharmacist

fujiir@hirakata.kmu.ac.jp072-804-0101

Outcome results